Kyle is a fifth-year PhD student in the pharmacology program at Weill Cornell, originally hailing from Pickerington, Ohio. After discovering his passion for science during his undergraduate studies at the University of Notre Dame, exploring the fields of natural products discovery and synthesis, protein biochemistry, and medicinal chemistry in both academic and industry environments, he found his scholastic home in the Rhee lab. There, his F31-funded research includes deciphering the complex mechanism of action of tryptophan biosynthesis inhibitors—which represent a promising avenue for novel TB drug development—developing and optimizing a high-throughput workflow for measuring druglike compound accumulation in M. tuberculosis, and collaborating with members of other research groups to investigate the metabolic footprints of candidate TB drug molecules. Outside of the laboratory, he enjoys riding his bike and exploring new corners of New York City, attempting to keep his indoor plants alive, and spending too much money on iced coffee. After completing his PhD, Kyle aims to pursue medical education and a career as a clinician-scientist, working to reduce health disparities, discover better treatment and prevention strategies for infectious diseases, and provide high-quality, compassionate care to the people affected by them.
Science Twitter Handle: @pharmakyle